Three-dimensional drug screen identifies HDAC inhibitors as therapeutic agents in mTORC1-driven lymphangioleiomyomatosis
A. Pietrobon, J. Yockell-Lelievre, N. Melong, L. J. Smith, S. P. Delaney, N. Azzam, C. Xue, N. Merwin, E. Lian, A. Camacho-Magallanes, C. Dore, G. Musso, L. M. Julian, A. S. Kristof, R. Y. Tam, , W. L. Stanford
A 3D drug screen identified HDAC inhibitors as effective against mTORC1-driven lymphangioleiomyomatosis by reducing invasion and selectively killing TSC2-/- cells.
bioRxiv · Jul 3, 2021Cell Biology